ClinicalTrials.gg
RecruitingNCT06886464PONTiAKUpdated Nov 13, 2026

Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin

A Phase 2 interventional study of Cilastatin Sodium and Placebo-Saline in Acute Kidney Injury, sponsored by Matthew James. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Matthew James · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 13, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
698
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Acute Kidney Injury with a site in Canada — 19 open to participants now, 22 under way, 1 of them phase 3. Acute Kidney Injury · Canada.

Planned enrollment
10th of 54
698 · median 137
Started
2025
with 5 others
Phase 2
16 of 83
3 open now
Primary completion
2027-12
later than 15 of 21 live
Registered
78th of 83
by date

Among the 83 studies in Acute Kidney Injury with a site in Canada, this one is the 10th largest by planned enrollment of the 54 interventional ones that give a count, is one of 6 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 15 of the 21 other live ones, and was the 78th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

19 of the 83 studies in Acute Kidney Injury with a site in Canada are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Acute Kidney Injury with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to repurpose cilastatin for preventing acute kidney injury (AKI) in hospitalized patients receiving nephrotoxic medications. The trial will evaluate the efficacy of the re-purposed drug.

The main questions it aims to answer are:

- whether cilastatin will prevent nephrotoxic AKI in hospitalized patients.

Researchers will compare the drug cilastatin to a placebo (a look-alike substance that contains no drug) to see if drug cilastatin works to prevent AKI in hospitalized patients receiving nephrotoxic medications.

Participants will:

  • Receive drug Cilastatin or a placebo intravenously every 6 hours for up to 24 hours after last exposure to nephrotoxic medication
  • Have blood test for kidney function every day they are on treatment.
  • Have a follow-up blood test at 90 days after randomization
  • Have a telephone survey at 90 days after randomization
Read the detailed description

BACKGROUND People living with chronic diseases frequently require hospitalization, where they are often exposed to a variety of medications. Common medications include drugs for the treatment of cancer, immunosuppression for organ transplantation or autoimmune conditions, antibiotics for infections, and contrast dyes for imaging procedures. Many of these medications can be nephrotoxic and cause iatrogenic acute kidney injury (AKI) in 25% of hospitalized patients, especially among those receiving combinations of multiple medications. The long-term consequences of AKI are many, and include prolonged hospitalization, increased risk of readmission, progression of chronic kidney disease (CKD), and kidney failure. AKI also affects other organ systems and increases the risk of major adverse cardiovascular (CV) events and death. AKI has a profound effect on long-term patient outcomes and places a high burden on the health system by both increasing resource use for acute care as well as those for long-term chronic disease management.

The incidence of AKI has been rising by 10% annually and is highest in people aged 65 and older and among those with pre-existing chronic diseases. As more patients experience AKI, the health burden resulting from these outcomes has become increasingly apparent, with rising rates of progression to CKD, kidney failure, CV events and death. Although nephrotoxic AKI is common and associated with poor outcomes, there is currently a lack of effective preventive strategies other than drug avoidance, which is suboptimal as it denies vulnerable patients from receiving many effective medical therapies.

Clinical Issue and Opportunity:

Nephrotoxic AKI is common among hospitalized patients and there are currently no pharmacologic therapies available for prevention. The Nephrotoxic Injury Negated by Just-In-Time Action (NINJA) research initiative has developed, implemented, and evaluated strategies to identify patients at high risk of nephrotoxic AKI, with the objective of improving identification of high risk patients and reducing harm related to AKI . Several studies employing NINJA criteria have demonstrated an incidence of nephrotoxic AKI of 20-30% among hospitalized patients with multiple medication exposures, including with antibiotics (vancomycin, aminoglycosides), radiographic contrast dye, and calcineurin inhibitors identified among the most commonly associated agents. In hospitalized adults in North America, antibiotics and iodinated contrast are implicated in more than half of all nephrotoxic AKI. Trying to avoid exposure to these medications is suboptimal as it denies patients from receiving the best available therapies. The implementation of a common computerized clinical information system across all hospitals in Alberta provides an opportunity to efficiently identify patients with high risk nephrotoxic medication exposures, and test interventions to prevent AKI and its downstream consequences.

Current Evidence:

CIHR funded studies from our institution and others have identified tubular uptake of nephrotoxins as a major contributor to the pathogenesis of AKI. Dipeptidase-1 (DPEP1) and megalin (LRP2) are proteins that contribute to the uptake of nephrotoxic drugs in the proximal tubules of the kidney. DPEP1 is also a major non-classical leukocyte adhesion receptor that is critical in neutrophil and inflammatory monocyte recruitment to the kidney.

Cilastatin is a small molecule developed and approved for human use as an enzymatic DPEP1 inhibitor to prevent degradation of the antibiotic imipenem. Through the inhibition of DPEP1 and LRP2, cilastatin has proven effective in preventing tubular drug uptake and kidney injury in cell culture and animal models of nephrotoxic AKI from contrast, vancomycin, gentamicin, cisplatin, and cyclosporine. Cilastatin also prevents DPEP1-mediated kidney injury from a variety of causes mediated by inflammation. For these reasons, cilastatin has been indirectly tested in human studies for nephrotoxic AKI prevention, using imipenem-cilastatin formulations approved for clinical use.

A systematic review identified 10 studies (5 RCTs, n=535 patients; 5 observational comparative effectiveness studies n=6,198) that evaluated the nephroprotective effects of imipenem-cilastatin in patients receiving a variety of nephrotoxic medications including calcineurin inhibitors, antibiotics, and chemotherapy. All identified studies reported lower risk of kidney injury (pooled risk ratio 0.54 [95% CI, 0.41 to 0.72] and/or better kidney function between 7 to 30 days after treatment among patients receiving imipenem-cilastatin than comparator groups.

Rationale for Study:

Repurposing cilastatin to target tubular toxin/drug uptake and renal inflammation represents a highly promising and scientifically rational approach to protect the kidney from nephrotoxic AKI and ultimately improve kidney and CV outcomes for patients.

The PONTiAK Study will apply innovative electronic recruitment and data collection methods to complete a randomized Study to efficiently generate new evidence on the efficacy of this treatment strategy. Collectively, the Study will produce valid and generalizable results that will not only inform a pivotal phase 3 Study but also accelerate methods for efficiently and effectively conducting such a clinical Study needed for eventual drug approval. If cilastatin reduces the incidence of nephrotoxin-induced AKI by 10%, it would significantly change clinical practice, preventing more than 10,000 episodes of AKI in Canada each year. This significant AKI reduction has the potential to reduce hospitalization and downstream adverse kidney and CV events, saving \~$78 million annually.

STUDY DESIGN AND WORKFLOW

The PONTiAK Study is a randomized, double blind, placebo-controlled superiority study in hospitalized adults at risk of nephrotoxic AKI. Eligible Participants will be identified using a computer-enabled case finding algorithm for patients with nephrotoxic medication exposures implemented in the common clinical information system called Connect Care used in the six largest hospitals in Alberta. The case finding approach will be adapted from NINJA, an evidence-based algorithm defined by exposure to three medications on the same day from an evidence-based list of 47 drugs from 7 medication classes (plus radiocontrast dyes), or prescription of an aminoglycoside antibiotic or vancomycin for 3 or more days. NINJA is a validated approach to enrich for identification of hospitalized patients at high risk of AKI. Patients meeting the nephrotoxin exposure criteria with an active order for a medication that mediates AKI via DPEP1/LRP2 uptake will be identified daily and approached to obtain informed consent then randomized 1:1 to cilastatin or placebo using a central web-based system. In addition to hospitalized patients, patients receiving eligible chemotherapeutics drugs (eg. platins) in day medicine units of hospitals will also be identified by the algorithm and approached for recruitment.

Treatment with IV cilastatin or matching placebo will be initiated as soon as possible after randomization and continued for up to 24 hours after last exposure to nephrotoxic medication for medications requiring repeated dosing, hospital discharge, or initiation of dialysis. Day Medicine patients will receive IV cilastatin or matching placebo one time immediately before receiving the nephrotoxic medication (typically at the time of pre-medication with IV fluid, anti-emetic, and analgesic administration). The study drug may be discontinued at any time based upon the patient's attending physician's or site investigator's judgement.

Participants will be followed daily in hospital following randomization for the duration of nephrotoxic medication exposure plus 48 hours or until hospital discharge. During this period daily measurements of kidney function (serum creatinine) will be collected in a standardized manner according to the NINJA lab testing algorithm to ascertain the primary outcome of AKI. Participants will also have vital signs and urine output results recorded daily throughout the treatment period and for 48 hours following the end of nephrotoxic medication treatment. Day Medicine patients will have vital signs recorded before and after IMP/placebo infusion, urine output recorded at the end of treatment with cisplatin or carboplatin, and blood work for kidney function done before IMP/placebo infusion and on day 2 and day 7 after nephrotoxic medication administration.

Adverse events will be recorded daily throughout the duration of treatment plus 48 hours. All Participants will also receive follow-up at 30 days following randomization, which will include electronic medical chart review, and assessment by telephone to ascertain the secondary outcomes of the study. To the extent possible, any adverse events that are deemed study drug-related and are ongoing at discharge will be followed-up to resolution or until a determination is made that the unresolved event is stable.

Consent will also be sought from all participants for linkage to routinely collected administrative health data to measure major adverse kidney and cardiovascular outcomes over an extended total of two years follow-up from study enrollment.

SAMPLE SIZE The Study will recruit 698 patients (349 per arm) to achieve 85% power to detect a 10% absolute risk reduction in the incidence of AKI from 25% in the placebo arm to 15% in the cilastatin arm, with a two-sided type 1 error rate of 0.05. The minimal clinically important difference for powering assumptions for the PONTiAK trial are informed by recommendations from existing literature on the design of AKI prevention clinical trials. Ten trials of imipenem-cilastatin versus placebo have been conducted in adults, and our updated systematic review produced a pooled odds ratio for AKI of 0.42 (95% CI 0.26-0.69), with a corresponding absolute risk reduction of 32% (95% CI 16 -77%). The investigators conducted power analysis by simulation considering a substantially smaller minimum clinically important absolute difference in AKI incidence of 10%. Assuming two event probabilities of 0.25 (placebo) and 0.15 (cilastatin) drawn from a binomial distribution, a two-sided type 1 error rate of 0.05 (applying a chi-square test), using at least 10,000 replicates of the experiment, the investigators found that 349 participants per arm would confer a power of 85% to the PONTiAK trial. With this sample size the trial will still have a power of 80% even with up to a 10% loss to follow-up.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • Acute Kidney Injury
  • Nephrotoxic
  • Cilastatin
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Active treatment with an eligible nephrotoxic medication- IV vancomycin, IV aminoglycoside (gentamicin or tobramycin), IV calcineurin inhibitor (cyclosporine or tacrolimus), or IV or intraperitoneal cisplatin, oxaliplatin or carboplatin; or intraarterial radiographic contrast with two or more high-risk nephrotoxic medication exposures according to the NINJA algorithm.
  • Able to provide or have an authorized representative available and willing to give written informed consent after being properly informed of the nature and risks of the Study.

Exclusion criteria

Exclusion Criteria:

  • Stage 3 AKI based on Kidney Disease Improving Global Outcomes (KDIGO) SCr or urine output criteria, or receipt of short-term dialysis.
  • Category G5 CKD (defined as a eGFR or \<15 mL/min/1.73 m2) or being treated with maintenance dialysis or a kidney transplant.
  • Pregnancy or lactation
  • Known to imipenem-cilastatin.
  • Active or recent treatment (within 48 hours) with imipenem-cilastatin
  • Active or recent treatment (within 48 hours) with probenecid (medication used for gout prevention that inhibits cilastatin excretion and decreases plasma clearance)
  • Participation in other drug trial (excluding Phase 4 trials with marketed drug) within 30 days.
  • Palliative goals of care (C1 or C2).
  • Inability to comply with the requirements of the Study protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
698 participants (estimated)

Study arms

  • Experimental
    Cilastatin Intervention

    Patients in this Arm will receive the Investigational Medicinal Product- Cilastatin

    Drug: Cilastatin Sodium

  • Placebo comparator
    Placebo Control

    Patients in this Arm will receive placebo

    Drug: Placebo-Saline

Interventions

  • DrugCilastatinStudies of CilastatinCilastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous cilastatin reconstituted in normal saline solution

    Also known as: Renal dehydropeptidase inhibitor

  • DrugPlacebo-Saline

    Identical looking normal saline solution

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Number of participants developing AKI

    Evaluation of Acute Kidney Injury (AKI) according to KDIGO serum creatinine (SCr) criteria; ≥ 26 mmol/L (0.3 mg/dL) increase in SCr within 48 hours or ≥50% increase in SCr within 7 days

    Time frame: 7 days after administration of a nephrotoxic medication

Secondary outcomes

  1. Number of participants developing stage-1, stage-2, and stage-3 AKI

    * Stage 1; SCr increase ≥26 μmol/L (≥0.3 mg/dL) or 1.5 - 1.9 times baseline. * Stage 2; SCr increase 2.0 - 2.9 times baseline. * Stage 3; SCr increase ≥3.0 times baseline OR increase in SCr ≥353.6 μmol/L (≥4.0 mg/dL) OR initiation of dialysis

    Time frame: Within 30 days of administration of nephrotoxic medication

  2. Number of participants needing dialysis

    Receipt of short or long-term dialysis

    Time frame: Within 30 days of administration of nephrotoxic medication

  3. Number of days admitted to hospital

    Hospital length of stay

    Time frame: Within 30 days of receiving nephrotoxic medication

  4. Measurement of eGFR and Cystatin C

    Kidney function based on SCr (eGFRSCr) and Cystatin C (eGFRCysC).

    Time frame: 90 days from study enrollment.

  5. Number of participants with SCr 1.5 times less than baseline

    Persistent decrease in kidney function, defined by SCr \> 26 μmol/L (≥0.3 mg/dL) or 1.5 times baseline

    Time frame: 90 days from study enrollment.

  6. Measurement of urinary albumin to creatinine ratio (ACR)

    Kidney damage based on urinary albumin to creatinine ratio (ACR)

    Time frame: 90 days from study enrollment.

  7. Hospital readmission

    Readmission to a hospital following a discharge (does not include interfacility transfer)

    Time frame: 90 days from study enrollment.

  8. All-cause mortality

    Death from any cause

    Time frame: 90 days from study enrollment.

  9. Physical and mental functional

    Physical and mental functional status based on short-form-12 (SF-12)

    Time frame: 90 days from study enrollment.

Other outcomes

  1. Number of participants developing Major Adverse Kidney Event (MAKE)

    Major adverse kidney (maintenance KRT, 40% decline in eGFRSCr, or death) event (MAKE) determined via administrative data linkage.

    Time frame: 2 years from study enrollment

  2. Major Adverse Cardiovascular Endpoint (MACE)

    Major adverse cardiovascular (myocardial infarction, stroke, hospitalization for heart failure or death) event (MACE) determined from patient administrative data.

    Time frame: 2 years from study enrollment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Elliott MJ, Fiest KM, Love S, Birdsell D, Loth M, Dumka H, Rana B, Shommu N, Benterud E, Gil S, Acharya D, Harrison TG, Pannu N, James MT. Patient Preferences and Priorities for the Design of an Acute Kidney Injury Prevention Trial: Findings from a Consensus Workshop. Kidney360. 2024 Oct 1;5(10):1455-1465. doi: 10.34067/KID.0000000000000554. Epub 2024 Aug 15. PubMed 39146029 ↗
  • Acharya D, Ghanim F, Harrison TG, Scory TD, Shommu N, Ronksley PE, Elliott MJ, Collister D, Pannu N, James MT. Nephroprotective Effects of Cilastatin in People at Risk of Acute Kidney Injury: A Systematic Review and Meta-analysis. Kidney Med. 2024 Oct 11;6(12):100913. doi: 10.1016/j.xkme.2024.100913. eCollection 2024 Dec. PubMed 39583177 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 39 non-industry phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 29 months is close to that.

Counting every sponsor, half of 57 studies reached it within 29 months; a quarter within 16 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 20, 2025
StartActual
Jul 16, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 2 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedActive treatment with an eligible nephrotoxic medication- IV vancomycin, IV aminoglycoside (gentamicin or tobramycin), IV calcineurin inhibitor (cyclosporine or tacrolimus), or IV or intraperitoneal platin-based chemotherapycisplatin, oxaliplatin or ifosfamidecarboplatin; or intraarterial radiographic contrast with two or more high-risk nephrotoxic medication exposures according to the NINJA algorithm.
Exclusion criteria
  • RemovedTreatment with another investigational medicinal product or participation in another interventional Study within 30 days
  • AddedParticipation in other investigational drug trial (excluding Phase 4 trials with marketed drug) within 30 days.
  • AddedPalliative goals of care (C1 or C2).
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedActive treatment with an eligible nephrotoxic medication- IV vancomycin, IV aminoglycoside (gentamicin or tobramycin), IV calcineurin inhibitor (cyclosporine or tacrolimus), or IV or intraperitoneal platin-based chemotherapycisplatin, oxaliplatin or ifosfamidecarboplatin; or intraarterial radiographic contrast with two or more high-risk nephrotoxic medication exposures according to the NINJA algorithm.
    Exclusion criteria
    • RemovedTreatment with another investigational medicinal product or participation in another interventional Study within 30 days
    • AddedParticipation in other investigational drug trial (excluding Phase 4 trials with marketed drug) within 30 days.
    • AddedPalliative goals of care (C1 or C2).
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06886464
Lead sponsor
Matthew James
Collaborators
Alberta Health services, University of Alberta
Responsible party
Matthew James (Sponsor-Investigator, University of Calgary) — Sponsor-investigator
First posted
Mar 20, 2025
Start date
Jul 16, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Nusrat S Shommu, PhD
Contact
nsshommu@ucalgary.ca
4032103991
Matthew T James, MD
principal investigator · University of Calgary

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilastatin

Start the discussion